A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Copper-gluconate/disulfiram (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors Cantex Pharmaceuticals
- 01 May 2017 Top-line results of the endpoints evaluated in this trial are expected in late 2017 and during the first half of 2018, according to a Cantex Pharmaceuticals media release.
- 01 May 2017 According to a Cantex Pharmaceuticals media release, dosing has been initiated in this trial.
- 04 Apr 2017 Topline results from this trial are expected in the second half of 2017, according to a Cantex Pharmaceuticals media release.